RESUMO
Two systems whose correlations cannot be classically accounted for display the simplest instance of quantum entanglement. Although this two-party association has caused a revolution in the foundations and uses of quantum mechanics, genuine entanglement among several parties unveils a whole new class of phenomena and applications. In this work we suggest a way to prepare Dicke states from a tunable source of bipartite entanglement to investigate foundational issues. The scheme has the following distinctive features: (i) it relies on controlled information loss and unentangled measurements; (ii) irrespective of the source entanglement, whenever a Dicke state is produced, it is ideal; (iii) the optimal entanglement of the bipartite source undergoes a second-order-like transition depending on the parameters of the Dicke state to be produced. These properties lead to asymptotic results on the entanglement between any qubit belonging to a Dicke state and the remaining qubits.
RESUMO
Hepatic glycogen metabolism is altered by nitric oxide (NO) during endotoxic shock. Thalidomide analogs immunomodulate the endotoxin-induced cytokines which regulate the NO release. We analyzed the short-term effects of some thalidomide analogs on the hepatic glycogen store and on the plasma and hepatic NO in an acute model of endotoxic challenge in rat. An endotoxin dose selection was performed. Rats received vehicle, thalidomide or analogs orally and, two hours after last dose, they were injected with endotoxin (5 mg/kg). Animals were sacrificed 2 h after challenge. Liver glycogen was quantified by the anthrone technique. Plasma and hepatic NO was determined by Griess reagent and HPLC. Hepatic interferon-gamma, a NO co-inducer, was measured by ELISA. Endotoxin caused inverse dose-dependent effects on plasma NO and on glycogen.Thalidomide analogs showed short-term regulatory effects on glycogen, some of them increased it. Plasma NO was almost unaffected by analogs but hepatic NO was strikingly modulated. Analogs slightly up-regulated the liver interferon-gamma and two of them increased it significantly. Thalidomide analogs may be used as a pharmacological tool due to their short-term regulatory effects on glycogen and NO during endotoxic shock. Drugs that increase glycogen may improve liver injury in early sepsis.
Assuntos
Endotoxinas/toxicidade , Glicogênio/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Óxido Nítrico/metabolismo , Talidomida/análogos & derivados , Talidomida/farmacologia , Animais , Relação Dose-Resposta a Droga , Fatores Imunológicos/química , Fatores Imunológicos/farmacologia , Interferon gama/metabolismo , Lipopolissacarídeos/toxicidade , Masculino , Óxido Nítrico/sangue , Ratos , Ratos Wistar , Fatores de TempoRESUMO
BACKGROUND: Several trials have been performed in the past using glucose, insulin, and potassium infusion (GIK) for the treatment of acute myocardial infarction (AMI). Because of continuing uncertainty about the potential role of this therapeutic intervention, we conducted a randomized trial to evaluate the impact of a GIK solution during the first hours of AMI. METHODS AND RESULTS: Four hundred seven patients with suspected AMI admitted within 24 hours of symptoms onset were enrolled. In a ratio of 2:1, 268 patients were allocated to receive GIK (high- or low-dose) and 139 to receive control. Phlebitis and serum changes in the plasma concentration of glucose or potassium were observed more often with GIK. A trend toward a nonsignificant reduction in major and minor in-hospital events was observed in patients allocated to GIK. In 252 patients (61.9%) treated with reperfusion strategies, a statistically significant reduction in mortality (relative risk [RR] 0.34; 95% CI: 0.15 to 0.78; 2P=0.008) and a consistent trend toward fewer in-hospital events in the GIK group were observed. CONCLUSIONS: Our results confirm that a metabolic modulation strategy in the first hours of an AMI is feasible, applicable worldwide, and has mild side effects. The statistically significant mortality reduction in patients who underwent a reperfusion strategy might have important implications for the management of AMI patients. It is now essential to perform a large-scale trial to reliably determine the magnitude of benefit.